The IPO registration statement is for 11.3 million shares of its Class A common stock, and the selling stockholders plan to grant underwriters a 30-day option to purchase up to 1.7 million additional shares of Class A common stock at the public offering price, less underwriting discounts and commissions.
In September 2020, Amwell upsized the price of its IPO to 41.2 million shares of its Class A common stock at $18 per share. The telehealth company at that time said the total proceeds of the IPO are expected to hit $742 million before deducting underwriting discounts, commissions and offering expenses.
Morgan Stanley, Goldman Sachs & Co. and Piper Sandler are the lead joint book-running managers for the offering.
More articles on telehealth:
‘We should look at broadband like we look at electricity and plumbing’: Jefferson Health CEO on telehealth equity
HHS invests $8M in telehealth broadband pilot
Amwell launches remote psychiatry service: 4 details
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
